Cochrane · systematic review · CD013106
Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B
Liang, N, Kong, DZ, Lu, CL, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
3
No studies
5
Included studies
NR
No studies 5 · 62.5%Ungraded 0 · 0%Very low 3 · 37.5%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B
Population: chronic hepatitis B
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Radix Sophorae flavescentis vs other drugs or herbs | no estimate extracted | NR | No studies |
Proportion of participants with ≥ 1 serious adverse events Radix Sophorae flavescentis vs other drugs or herbs | no estimate extracted | NR | No studies |
Health‐related quality of life Radix Sophorae flavescentis vs other drugs or herbs | no estimate extracted | NR | No studies |
Hepatitis B‐related mortality Radix Sophorae flavescentis vs other drugs or herbs | no estimate extracted | NR | No studies |
Hepatitis B‐related morbidity Radix Sophorae flavescentis vs other drugs or herbs | no estimate extracted | NR | No studies |
Proportion of participants with ≥ 1 adverse events considered 'not to be serious' (at maximum Radix Sophorae flavescentis vs other drugs or herbs | RR 0.86 [0.42, 1.75] | 2 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Exploratory outcome: Proportion of participants with detectable HBV‐DNA (at maximum Radix Sophorae flavescentis vs other drugs or herbs | RR 1.14 [0.81, 1.63] | 8 studies · 719 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Exploratory outcome: Proportion of participants with detectable HBeAg (at maximum Radix Sophorae flavescentis vs other drugs or herbs | RR 0.86 [0.75, 0.98] | 7 studies · 588 participants | Very low Downgraded: risk of bias, imprecision, publication bias |